Neurology

Video from the National Multiple Sclerosis Society with the message, "MS Kills Connection. Connection Kills MS."

Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.

This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.

This video summarizes the research findings from ECTRIMS 2012.

EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced today that the FDA approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

A recent study featured in the American Journal of Pharmacy Benefits examines the role of patient out-of-pocket cost on adherence to disease-modifying therapies for multiple sclerosis.

A new study indicates that starting HRT within 5 years of the onset of menopause is key to producing a neuroprotective effect.

In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.

A new study carried out by Blue Cross and Blue Shield of Minnesota and PBM Prime Therapeutics forecasts that multiple sclerosis specialty drug treatment cost will exceed $50,000 per person per year in 2016.

By the end of this year, it is likely that the FDA will approve more than 20 new specialty medications.

Eli Lilly's investigational monoclonal antibody failed to reach its primary endpoints, but it was associated with a significant slowing of cognitive decline in patients with mild Alzheimer's disease.

Genzyme, a Sanofi company, announced that the FDA has approved Aubagio (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

Less than a quarter know that most fractures in epilepsy patients are unassociated with seizures, according to a recent study.

The authors of a comprehensive literature review offer broad recommendations for treating super-refractory status epilepticus.

Elderly patients taking carbamazepine in conjunction with phenytoin experience a reduced increase in carbamazepine levels, a study finds.

Teva Pharmaceutical Industries Ltd and Active Biotech announced they will continue the clinical development of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) in a third Phase III trial.

There are great challenges to gaining approval for new antiepileptic drugs to be used as monotherapy, but a recent article offers ideas for ways forward.

A number of recent studies have investigated the relationship between epilepsy and depression, providing insights into both conditions.

More epilepsy surveillance data is needed in order to improve quality of life for people with the condition, an Institute of Medicine report suggests.

New research raises questions about the efficacy of one of the most commonly prescribed drugs used to treat relapsing-remitting multiple sclerosis.

An analysis of the top 200 drugs by prescriptions dispensed and total sales reveals key trends in today's pharmaceutical market.

Sanofi's Genzyme unit announced in a press release earlier last week that the company has submitted an application to regulatory authorities for approval of Lemtrada (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

Biogen Idec recently announced that United States and European Union regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS).

The Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).

Environmental factors may contribute to up to a quarter of neurodevelopmental disorders, but more research into the role of specific substances is needed.